Marconi testing MR and NM oncology tools
Marconi Medical Systems is expanding its oncology business beyond CT to MR and nuclear medicine with new screening tools and is signing business agreements with several companies and international health centers.Marconi formally launched its
Marconi Medical Systems is expanding its oncology business beyond CT to MR and nuclear medicine with new screening tools and is signing business agreements with several companies and international health centers.
Marconi formally launched its oncology division in 1998. Since then, the company has expanded research and development in this division beyond the CT simulation with which it began.
Marconi and Elekta Oncology Systems have signed a global distribution agreement allowing U.K.-based Elekta to sell the Marconi AcQsim CT simulation system software package.
Elekta makes linear accelerators, which deliver intensity-modulated radiation and intensity-modulated arc therapy.
Through the agreement, customers will be able to purchase the AcQsim system as a simulation package either from Marconi or from Elekta, if it will be used with a linear accelerator.
Marconis oncology business will now include Fox Chase Cancer Center in Philadelphia through a collaborative agreement that allows Marconi to use the center to conduct clinical beta test evaluations for MR simulation. Marconi also has an agreement with the Assistance Public at Tenon in Paris.
Marconi is working with Toronto Sunnybrook Regional Cancer Centre in Canada to conduct clinical tests with its Gamma PET. Toronto Sunnybrook has conducted clinical evaluations using the fusion of images from Gamma PET and CT for oncology simulation and planning, said Kathy Mah, senior physicist at Toronto Sunnybrook.
In addition, Marconi has signed a nonexclusive contract with Consorta Catholic Resource Partners to provide a full line of computed tomography, three-dimensional CT simulation systems, and nuclear medicine products.
Marconis Consorta contract includes multislice and single-slice CT scanners, single-, double-, and triple-head nuclear medicine gamma cameras and a full line of 3-D CT simulation systems. The featured products within each modality are the Mx8000 multislice CT scanners, the Axis gamma camera, and AcQsim.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
